Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

General

General

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • General
  • News

ProQR Gives Preclinical Proof Of Concept Data For AX-0810 Axiomer RNA Editing Program Targeting NTCP For Cholestatic Diseases

By Benzinga Newsdesk
May 8, 8:27 AM
ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing

PRQR

Read More
1 minute read
  • Biotech
  • General
  • News

Fulcrum Therapeutics Announces Publication Of Results From Phase 2b Clinical Trial Of Losmapimod In Facioscapulohumeral Muscular Dystrophy In The Lancet Neurology

By Benzinga Newsdesk
May 8, 8:13 AM
― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial――

FULC

Read More
3 minute read
  • Biotech
  • General
  • News

Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease

By Benzinga Newsdesk
May 8, 8:12 AM
Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected IND for PM359 recently cleared

PRME

Read More
1 minute read
  • Earnings
  • Equities
  • General
  • Guidance
  • Movers
  • News

Why Budweiser Parent Anheuser-Busch InBev’s Shares Are Taking Off Today

By Shivani Kumaresan
May 8, 8:09 AM
Discover why Anheuser-Busch InBev is surging post-earnings! With a 2.6% sales growth in Q1 FY24, beating estimates, the beverage giant showcases resilience amid market shifts.

BUD

Read More
2 minute read
  • General
  • Government
  • News
  • Politics
  • Tech

Joe Biden Set To Unveil Microsoft’s $3B AI Data Center Plan On Same Wisconsin Land Where Trump Tried To Execute His Mega Foxconn Fantasy

By Benzinga Neuro
May 8, 8:08 AM
Biden's announcement comes as part of his efforts to promote bipartisan legislation on infrastructure and semiconductor subsidies.

MSFT

Read More
1 minute read
  • Biotech
  • General
  • News

Lipocine Announces Late Breaking Oral Presentation Of Data From The Phase 2 Study Of LPCN 1148 At EASL Congress 2024

By Benzinga Newsdesk
May 8, 8:04 AM
Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of

LPCN

Read More
2 minute read
  • Equities
  • General
  • Markets
  • News

‘Is He Trying To Be Cramer?’ Elon Musk Pokes Fun At Gary Black’s Old Comments On Rivian As Tesla Rival Struggles To Make Its Mark

By Benzinga Neuro
May 8, 7:35 AM
Black had estimated Rivian's market cap at around $70 billion, assuming the company would produce 150,000 electric vehicles per year by 2024.

RIVN

Read More
2 minute read
  • Equities
  • General
  • Media
  • News

Amazon, Telefonica’s Bold Venture To Transform Telecommunications – What’s On The Cards?

By Shivani Kumaresan
May 8, 6:44 AM
Telefonica SA's German branch is set to migrate one million 5G users to Amazon Web Services (AWS) this month, marking a groundbreaking partnership. This move, a first for established mobile operators, signals a seismic industry shift towards public clouds, boosting efficiency and scalability.

AMZN

Read More
2 minute read
  • Equities
  • General
  • M&A
  • Markets
  • News

Byron Allen On Paramount-SkyDance Merger: ‘We Want To Buy All The Shares, Take It Private’

By Benzinga Neuro
May 8, 6:35 AM
Media magnate Byron Allen has shown interest in acquiring Paramount Global (NASDAQ:PARA) (NASDAQ:PARAA), intending to privatize it before…

PARA

Read More
2 minute read
  • Biotech
  • General
  • Health Care
  • News

AstraZeneca Pulls Plug On Vaxzevria COVID-19 Vaccine Amid Surplus of Updated Vaccines

By Benzinga Neuro
May 8, 6:23 AM
It is worth noting that AstraZeneca has previously conceded in court documents that Vaxzevria can induce side effects such as blood clots and low blood platelet counts.

AZN

Posts pagination

Previous 1 … 123 124 125 … 2,367 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service